EU/3/01/027: Orphan designation for the patent ductus arteriosus in premature neonates of less than 34 weeks of gestational age

Ibuprofen

Table of contents

Overview

This product was withdrawn from the Community Register of designated orphan medicinal products in July 2008 on request of the sponsor.

On 5 March 2001, orphan designation (EU/3/01/027) was granted by the European Commission to Orphan Europe, France, for ibuprofen for the prevention of patent ductus arteriosus in premature neonates of less than 34 weeks of gestational age.

Key facts

Active substance
Ibuprofen
Intended use
Patent ductus arteriosus in premature neonates of less than 34 weeks of gestational age
Orphan designation status
Withdrawn
EU designation number
EU/3/01/027
Date of designation
06/03/2001
Sponsor
Orphan Europe
Immeuble Le Wilson
70 Avenue du Général de Gaulle
F-92800 Puteaux
France
Telephone: +33 1 47 73 64 58
Telefax: +33 1 49 00 18 00
E-mail: info@orphan-europe.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating